Could buying this gene-editing penny stock at $1 make me rich?
This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA.
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment
Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Vertex Pharmaceuticals announces MHRA approval of ALYFTREK for CF
Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...
MoneyWeek on MSN18h
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...